We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Orion Corporation | TG:OFK | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 0.40% | 37.74 | 37.67 | 37.81 | 37.72 | 37.68 | 37.68 | 70 | 22:50:06 |
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE26 APRIL 2024 at 11.15 EEST
Composition of the Nomination Committee of Orion Corporation
The Board of Directors of Orion Corporation has appointed the following persons to the Nomination Committee of the company:
Hilpi Rautelin was appointed as Chair of the Committee.
The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board.
The essentials of the charter of the Nomination Committee and a description of the appointment process of its members are provided at https://www.orion.fi/en/investors/corporate-governance/board-of-directors/nomination-committee/charter-of-the-nomination-committee/ , a page in the Corporate Governance section of the Orion Group website.
Orion Corporation
Liisa HurmePresident and CEO | Olli HuotariSVP, Corporate Functions |
Contact person:Olli Huotari, SVP, Corporate Functions, Secretary to the Board of Directors of Orion Corporation
tel. +358 10 426 3054
Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orion.fi/en http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
1 Year Orion Chart |
1 Month Orion Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions